Autres langues PAVmed Inc.

Actions

PAVM

US70387R4039

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 02/05/2024			Varia. 5j.	Varia. 1 janv.
2,24 ^USD	-3,03%		+26,55%	-45,63%

27/03	Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
25/03	PAVmed Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024	02/05
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	30/04
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month	29/04
PAVmed : Material Agreement - Form 8-K	26/04
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	08/04
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21/03
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21/03
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference	20/03
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024	13/03
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024	12/03
PAVmed : Failure to Satisfy Listing Rule - Form 8-K	08/03
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	19/02
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	16/02
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony	15/02
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	09/02
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	08/02
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12/12
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders	11/12
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split	04/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PAVmed Inc.

Actions

PAVM

US70387R4039

Autres langues

Filtres